Concurrent gemcitabine and 3D radiotherapy in patients with stage III unresectable non-small cell lung cancer

Autor: RM Pieterman, Gerald S. M. A. Kerner, Ellen M Driever, Thijo J N Hiltermann, Edwin Blokzijl, Marc J F Mertens, Harry J.M. Groen, John W. G. van Putten, Erwin M. Wiegman, Jeroen J W Liesker, Leon F. A. van Dullemen, Tineke E. J. Renkema, Joachim Widder
Přispěvatelé: Guided Treatment in Optimal Selected Cancer Patients (GUTS), Translational Immunology Groningen (TRIGR)
Jazyk: angličtina
Rok vydání: 2014
Předmět:
Male
Oncology
Radiation-Sensitizing Agents
Lung Neoplasms
medicine.medical_treatment
Kaplan-Meier Estimate
PACLITAXEL
Deoxycytidine
chemistry.chemical_compound
CHEMORADIATION
CONSOLIDATION DOCETAXEL
Carcinoma
Non-Small-Cell Lung
Antineoplastic Combined Chemotherapy Protocols
INDUCTION CHEMOTHERAPY
ONCOLOGY-GROUP
THORACIC RADIOTHERAPY
Aged
80 and over
Chemoradiotherapy
Middle Aged
I TRIAL
Concurrent chemoradiotherapy
Treatment Outcome
Radiology Nuclear Medicine and imaging
Female
medicine.drug
Adult
medicine.medical_specialty
Vinblastine
Disease-Free Survival
Internal medicine
medicine
Humans
Radiology
Nuclear Medicine and imaging
Lung cancer
Aged
CARBOPLATIN
Radiotherapy
business.industry
Research
Induction chemotherapy
RANDOMIZED PHASE-III
medicine.disease
Gemcitabine
Carboplatin
Radiation therapy
chemistry
RADIATION
Cisplatin
Radiotherapy
Conformal
Stage III NSCLC
business
Esophagitis
Zdroj: Radiation oncology, 9:190. BMC
Radiation Oncology (London, England)
ISSN: 1748-717X
Popis: Background: Stage III unresectable non-small cell lung cancer (NSCLC) is preferably treated with concurrent schedules of chemoradiotherapy, but none is clearly superior Gemcitabine is a radiosensitizing cytotoxic drug that has been studied in phase 1 and 2 studies in this setting. The aim of this study was to describe outcome and toxicity of low-dose weekly gemcitabine combined with concurrent 3-dimensional conformal radiotherapy (3D-CRT).Patients & methods: Treatment consisted of two cycles of a cisplatin and gemcitabine followed by weekly gemcitabine 300 mg/m(2) during 5 weeks of 3D-CRT, 60 Gy in 5 weeks (hypofractionated-accelerated). Overall survival (OS), progression-free survival (PFS), and treatment related toxicity according to Common Toxicity Criteria of Adverse Events (CTCAE) version 3.0 were assessed.Results: Between February 2002 and August 2008, 318 patients were treated. Median age was 64 years (range 36-86); 72% were male, WHO PS 0/1/2 was 44/53/3%. Median PFS was 15.5 months (95% confidence interval [CI], 12.9-18.1) and median OS was 24.6 months (95% CI., 21.0-28.1). Main toxicity (CTCAE grade >= 3) was dysphagia (12.6%), esophagitis (9.6%), followed by radiation pneumonitis (3.0%). There were five treatment related deaths (1.6%), two due to esophagitis and three due to radiation pneumonitis.Conclusion: Concurrent low-dose gemcitabine and 3D-CRT provides a comparable survival and toxicity profile to other available treatment schemes for unresectable stage III.
Databáze: OpenAIRE
Externí odkaz: